Personalized medicine looks set to transform the biopharmaceutical landscape, and will demand significant changes in production methods. The demand for large-scale batch processes will decline – so what is the alternative? The UK’s new National Biologics Manufacturing Center is on a mission to answer that very question.
Jonathan Robinson |
As recently as 2009, the UK had the second strongest pharmaceutical industry in the world, but in recent years we have seen the sector falter. The UK is falling behind – fewer new drugs are being discovered here and drug manufacturing is drifting overseas. The UK government recognizes the value of the country’s significant expertise within the life sciences sector and wants to make sure we retain our leading position. To that end, a raft of government initiatives are being implemented to support UK life sciences companies and encourage them to develop and manufacture innovative new therapies within the UK. This includes the National Biologics Manufacturing Centre (NBMC), the Precision Medicine Catapult, the Cell Therapy Catapult and the Medicines Technology Catapult.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.